It seems clear to me the trial is on again-off again "study" with no connection to FDA fast track or commercialization. Perhaps compassionate use for patients in some extremely limited way. Perhaps in the mix for some future I/O. Liau gets some nice recognition. Powers gets a pat on the back for finding funds for the university/hospital. Shareholders and Woodford left holding their things.
News 
Market Data 
Discover 
AI
